

Carbon reduction plan

Supplier name: AstraZeneca PLC

Publication date: April 2025

Commitment to achieving net zero

Through Ambition Zero Carbon, AstraZeneca are on track to reduce Scope 1 and 2 greenhouse gas (GHG) emissions from our global operations by 98% by 2026 from a 2015 baseline. We aim to halve our entire value chain footprint by 2030, on the way to a 90% reduction by 2045 from a 2019 baseline. We aim to be science-based net zero by 2045.ⁱ

We are pursuing ambitious science-based decarbonisation targets, accelerating our progress towards net zero, and managing the risks and opportunities presented by climate change:

- We follow the science to understand the climate and health nexus and set our targets
- We follow a hierarchy to address each emission source (eliminate-reduce-substitute)
- We recognise the importance of our supply chain and suppliers, whom we engage with, educate, support and incentivise to act
- We partner with our sector peers, including at a high-level through the Sustainable Markets Initiative Health Systems Task Force and in addressing key emissions sources through the Energize and Activate collaborations
- We are transparent about our performance, methodologies, transition plan and assessment of climate-related risks and opportunities presented by a low-carbon economy and net-zero healthcare
- We have nature-based and technical measures in place to identify and address physical climate risks at site level and in local business continuity planning
- We focus on delivering absolute reductions in all our direct and indirect GHG emissions sources across the value chain – Scopes 1, 2 and 3.

Baseline emissions footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2015 for Scope 1 & 2, 2019 for Scope 3	
Additional details relating to the baseline emissions calculations	
<p>AstraZeneca reports greenhouse gas (GHG) emissions in accordance with the World Resource Institute / World Business Council for Sustainable Development (WRI/WBCSD) Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard, Revised Edition (2015) and Corporate Value Chain (Scope 3), Accounting and Reporting Standard (2011). This data is reported at the global enterprise level and therefore data in this CRP submission will utilise this data.</p> <p>AstraZeneca Scope 1 & 2 performance is tracked relative to a 2015 baseline year. Scope 3 performance is tracked relative to a 2019 baseline year. The baseline years are representative of normal operating conditions and the difference in baseline years between emission scopes is due to availability of data. Emissions are reported on a calendar year basis (1 January – 31 December).</p> <p>Recalculations to baseline GHG data occurs to ensure that real changes to emissions are captured rather than a result of AstraZeneca structural (acquisitions, divestments, mergers) or methodology changes (error correction or calculation adjustments). This enables consistency to be maintained over time. Recalculation will be considered dependent upon significance to GHG emissions with updates disclosed. An internal procedure sets out the thresholds and process for recalculation and that adjustments are logged and communicated to our assurance partners as part of annual reporting.</p>	
Baseline year emissions: 2015 & 2019	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	298,498 (2015)
Scope 2	322,319 (2015) (Market Based)
Scope 3 (Included Sources)	5,722,797 (2019)
Total Emissions	N/A

Current emissions reporting

Reporting Year: 2024	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	125,386
Scope 2	14,210 (Market Based)
Scope 3 (Included Sources)	5,897,822
Total Emissions	6,037,318

Emissions reduction targets

We follow the science and focus our activities on delivering absolute reductions in all our direct and indirect GHG emissions sources across the value chain – Scopes 1, 2 and 3.

- Reduce absolute Scope 1 and 2 GHG emissions by 98% by 2026, from 2015 base year.
- 100% electric road fleet where technically possible by the end of 2025.
- Reduce total energy consumption from sites by 10% from 2015 to 2025.
- Double energy productivity from 2015 to 2025.
- 100% renewable electricity consumption globally by 2025.
- Reduce absolute Scope 3 GHG emissions by 50% by 2030 and 90% by 2045, from a 2019 base year.
- Increase the share of primary activity data in Scope 3 reporting in 2025.
- 95% of our suppliers by spend covering purchased goods and services and capital goods, and 50% of our suppliers by spend covering upstream transportation and distribution and business travel, will have SBTs by end of 2025.
- From 2025, AstraZeneca pMDI portfolio will begin to use a next-generation propellant (NGP) with 99.9% lower GWP than in today's medicines,ⁱⁱ subject to regulatory approvals.

Carbon reduction projects

Completed carbon reduction initiatives

The following environmental management measures and projects have been completed or implemented since the 2015 Scope 1 & 2 baseline. The carbon emission reduction achieved by these schemes equate to 481,224 tCO₂e, a 77.5% reduction against the 2015 Scope 1 & 2 baseline and the measures will be in effect when performing the contract.

To drive our climate action initiatives and meet our environmental targets, we have a dedicated Natural Resource Efficiency Fund (NREF) in environmental efficiency projects since 2015. We have

achieved a 20% absolute reduction in total energy consumption from our 2015 baseline and are committed to using 100% renewable energy sources to meet all our needs by the end of 2025.

In 2021, we transitioned to 100% imported electricity from certified renewable sources through purchasing certificates from the same country, and same year, as our consumption. As we were unable to purchase renewable electricity certificates for Russia in 2022, this reduced to 99% and was maintained in 2024.

We have entered into a 15-year agreement with Future Biogas to establish the first unsubsidised industrial-scale supply of biomethane in the UK. Since February 2025, this supply of renewable energy is now contributing the equivalent requirement of our sites in Macclesfield, Cambridge, Luton and Speke. The new biomethane plant is expected to supply more than 100 gigawatt hours (GWh) of biomethane, equivalent to 20% of our total global gas consumption. Using crops grown locally as part of diverse crop rotations, the plant also contributes to the development of a circular economy, supporting UK farms with sustainable land management practices. Similar schemes are being developed in China and the US, the latter enabling up to 46% of AstraZeneca's total global gas consumption.

AstraZeneca is also working in partnership with the NHS to reduce emissions in care pathways. For example, the SENTINEL Project is an on-going quality improvement initiative co-developed with clinicians and patients to improve asthma outcomes while reducing SABA-over reliance. The last published data reported 44,275 fewer blue inhalers being issued, saving 1,240 metric tonnes of carbon emissions, equivalent to 39,600 ambulance responses.^{iii,iv} The programme of work continues with roll out and in 2024 included supporting the Chief Sustainability Officer's Research Fellow to study the application of the COM-B behavioural change framework within the regional implementation of Sentinel Plus Quality Improvement Project.^v

We are investing \$400 million in the AZ Forest programme worldwide to restore nature, benefit local communities and compensate for residual emissions. We are aiming to plant more than one million trees in the UK by the end of this year, in collaboration with Forestry England.

To tackle our scope 3 emissions we aim for 95% of our key suppliers and partners by spend will have science-based targets by the end of 2025. We're working closely to support suppliers and partners to achieve this.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard^{vi} and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.^{vii}

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.^{viii}

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the supplier:

Paul Pambakian, Head of Corporate Affairs, UK

Date: 10 April 2025

GB-65810 Date of prep: April 2025

i <https://www.astrazeneca.co.uk/sustainability>

ii Pritchard J. Drug Des Devel Ther 2020; 14: 3043-3055

iii Royal College of Physicians. Sentinel Project. Available online: <https://www.rcp.ac.uk/news-and-media/news-and-opinion/the-sentinel-project/> [Accessed Jan 2025]

iv Scoping ambulance emissions: recommendations for reducing engine idling time Available online:

<https://www.paramedicpractice.com/content/features/scoping-ambulance-emissions-recommendations-for-reducing-engine-idling-time/#:~:text=An%20average%20of%2031.3%20kg,current%20box%2Dshaped%20ambulance%20design>

v Available online: [COM-B behavioural change framework within the regional implementation of Sentinel Plus Quality Improvement Project](#)

vi <https://ghgprotocol.org/corporate-standard>

vii <https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

viii <https://ghgprotocol.org/standards/scope-3-standard>